Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2.44

 

EUR

 

+5.17 %

Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

4,771 following
Compare
+5.17%
+6.55%
+6.55%
+7.02%
+20.2%
+26.1%
+32.97%
-27.38%
-53.08%

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Read more
Market cap
37.04M EUR
Turnover
36.79K EUR
P/E (adj.) (24e)
15.81
EV/EBIT (adj.) (24e)
12.11
P/B (24e)
3.09
EV/S (24e)
2.05
Dividend yield-% (24e)
-
Coverage
Recommendation
Buy
Target price
2.90 EUR
Updated
23.12.2024
Disclaimer
Latest research

Latest analysis report

Released: 23.12.2024

Latest extensive report

Released: 02.07.2023

Financial calendar
12.2
2025

Annual report '24

4.6
2025

General meeting '24

6.8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analyst Comment by
Antti Siltanen

Biohit is working on a new market launch and FDA approval

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth.

Biohit
Biohit H1'24 preview: Opening of a new strategy period
Analyst Comment by
Antti Siltanen

Biohit H1'24 preview: Opening of a new strategy period

Biohit will release its H1 report on Wednesday, August 7 at 9:30 am EEST. We expect the company to continue healthy growth during the first six months of the new strategy period. We expect the result to be at the level of the comparison period, as growth investments increase costs.

Biohit
Analyst Comment by
Antti Siltanen

Biohit strengthens R&D

On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

Biohit
Analyst Comment by
Antti Siltanen

Biohit's Q1 has gone according to plan

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on schedule.

Biohit
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.